Leadership & Expert Views - Cancer Currents Blog
Commentaries from scientific leaders at NCI and other institutions about cancer research topics, programs, and initiatives.
-
People with HIV are often excluded from clinical trials to protect their safety. Preliminary results from an NCI-sponsored study of an immunotherapy drug show that people with HIV can safely participate in clinical trials.
-
November 26, 2017, marked a unique moment in US public health history, with the major US tobacco companies issuing the first in a series of court-ordered "corrective statements" about their products.
-
NCI’s Dr. Glen Morgan discusses NCI’s Cancer Center Cessation Initiative, including how and why this smoking cessation initiative was developed and its long-term goals.
-
Norman Sharpless, M.D., discusses his appointment as the director of the National Cancer Institute and his plans for continuing NCI’s long tradition of research excellence and commitment to improving people’s lives.
-
Progress continues to be made with the Gabriella Miller Kids First Research Program, which is creating opportunities for investigators from different research communities to share resources and collaborate on research into childhood cancers and certain birth defects.
-
NCI’s Dr. Rosandra Kaplan discusses important trends in metastatic cancer research and new ideas for treating and preventing metastatic cancer.
-
Researchers recognized the potential of endoxifen as a treatment for breast cancer and, with NCI support, developed the compound into a drug now being tested in clinical trials.
-
NCI’s Small Business Innovation Research Program recently issued contract solicitations to spur the development of new cancer-related therapies and technologies, including seven opportunities specific to the Cancer Moonshot.
-
The Discovery Channel special, First in Human, will feature some of the groundbreaking work on cancer immunotherapy being done at the NIH Clinical Center, including CAR T-cell therapy and TIL therapy.
-
Progress against the brain cancer glioblastoma has been slow. Drs. Mark Gilbert and Terri Armstrong of NCI’s Neuro-Oncology Branch discuss why and what’s being done to change that.